Dr Lal Pathlab Group CFO on Business Outlook

The transcript discusses the company's focus on growing its non-COVID business, which has seen a 28% growth in Q3. The company is expanding both organically and inorganically, with a focus on increasing its presence in Tier 2 and Tier 3 cities. Despite acquisitions impacting earnings, the company aims to grow through volume while maintaining margins. Supply chain management has been effective, with no significant disruptions in the supply of test kits.

What is the company's approach towards acquisitions and organic growth?

What challenges did the company face regarding supply chain disruptions?